Recently, the giants in the medical device field have successively released their latest financial reports. Behind these figures lie not only the increases and decreases on the financial statements but also the efforts and adjustments made by major companies in R&D, market strategies, and in response to challenges. Next, let’s take a look at the performance of these companies.

MedtronicAnnounced Financial Results for the Second Fiscal Quarter Ended October 25, 2024. Quarterly Net Sales Were $8.403 Billion, Compared to $7.984 Billion in the Same Period Last Year. Quarterly Operating Profit Was $1.595 Billion, Compared to $1.34 Billion in the Same Period Last Year. Quarterly Net Profit Attributable to the Company Was $1.27 Billion, Compared to $909 Million in the Same Period Last Year.

Johnson & JohnsonAnnouncement of Q3 2024 Financial Results. Quarterly sales reached $22.471 billion, compared to $21.351 billion in the same period last year, representing a year-over-year increase of 5.2%. Quarterly net profit was $2.694 billion, down 37.5% from $4.309 billion in the same period last year. Adjusted net profit was $5.876 billion, a decrease of 13.3% year-over-year. By business segment, pharmaceutical sales amounted to $14.58 billion, up 4.9% year-over-year. Medical device sales were $7.891 billion, an increase of 5.8% year-over-year.

AbbottAnnouncement of Q3 2024 Financial Results. Net sales for the quarter were $10.635 billion, compared to $10.143 billion in the same period last year, representing a 4.9% year-over-year increase. Quarterly net profit was $1.646 billion, compared to $1.436 billion in the same period last year. By business segment, sales from the medical device division were $4.747 billion, up 11.7% year-over-year. Sales from the nutrition business were $2.066 billion, down 0.3% year-over-year. Sales from the diagnostics business were $2.412 billion, down 1.5% year-over-year. Sales from the generics business were $1.406 billion, up 2.7% year-over-year.

Siemens HealthineersAnnouncement of Q4 and Fiscal Year 2024 Results Ended September 30, 2024. Q4 revenue was €6.329 billion (approximately $6.71 billion), compared to €6.056 billion in the same period last year, representing a 4.5% year-over-year increase. Adjusted EBIT profit was €1.12 billion, up from €1.045 billion, marking a 7% growth. Quarterly net profit reached €624 million, an increase of 15% from €540 million in the same period last year. Full-year revenue amounted to €22.363 billion, with adjusted EBIT profit at €3.51 billion and net profit at €1.959 billion.

Danaher Corporation (Danaher)Announcement of Q3 2024 Financial Results: Quarterly Sales Reach $5.798 Billion, Compared to $5.624 Billion in the Same Period Last Year; Net Profit Attributable to Ordinary Shareholders for the Quarter at $818 Million, Down from $1.129 Billion Last Year.

Medical Device and Equipment ManufacturersStrykerAnnouncement of Q3 2024 Financial Results: Net sales for the quarter were $5.494 billion, compared to $4.909 billion in the same period last year, representing an increase of 11.9% year-over-year. Quarterly net profit was $834 million, compared to $692 million in the same period last year, reflecting a year-over-year growth of 20.5%.

BDAnnouncement of Q4 and Fiscal Year 2024 Results Ended September 30, 2024. Q4 revenue was $5.437 billion, compared to $5.087 billion in the same period last year. Net profit attributable to ordinary shareholders for the quarter was $421 million, compared to $108 million in the same period last year. Fiscal year revenue was $20.178 billion, compared to $19.372 billion in the previous year. Net profit attributable to ordinary shareholders for the fiscal year was $1.726 billion, compared to $1.424 billion in the previous year.

Fresenius Medical CareAnnouncement of Q3 2024 Financial Results: Quarterly revenue was €4.76 billion (approximately $5.045 billion), compared to €4.936 billion in the same period last year, representing a 4% year-over-year decrease. Quarterly operating profit was €463 million, up 43% from €324 million in the same period last year. Quarterly net profit was €213 million, a 153% increase from €84 million in the same period last year.

GE HealthCarePublicMedtronic Reports Q3 2024 Earnings. Total revenue for the quarter was $4.863 billion, compared to $4.822 billion in the same period last year. Net income attributable to ordinary shareholders of the company for the quarter was $470 million, compared to $375 million in the same period last year.

Dutch Healthcare CompanyPhilips (Koninklijke Philips)Announcement of Q3 2024 Financial Results: Quarterly Sales Reach €4.377 Billion (Approx. $4.638 Billion), Compared to €4.471 Billion in the Same Period Last Year; Quarterly Operating Profit at €337 Million, Up from €224 Million Year-over-Year; Quarterly Net Profit at €181 Million, Rising from €90 Million the Previous Year. By Segment, Diagnostic and Treatment Business Sales Hit €2.15 Billion, Connected Care Business Sales Reached €1.211 Billion, and Personal Health Business Sales Were €835 Million.

Thermo Fisher ScientificAnnouncement of Q3 2024 Financial Results: Quarterly revenue was $10.598 billion, compared to $10.574 billion in the same period last year. Net profit attributable to the company for the quarter was $1.63 billion, compared to $1.715 billion in the same period last year. Specifically, Life Sciences business revenue was $2.387 billion, Laboratory Products and Biopharmaceutical Services revenue was $5.74 billion, Professional Diagnostics business revenue was $1.129 billion, and Analytical Instruments revenue was $1.808 billion.

RocheAnnouncing the performance for the first nine months of 2024. During this period, the group's sales reached 45 billion Swiss francs, compared to 44.1 billion Swiss francs in the same period last year. Among these, pharmaceutical business sales amounted to 34.3 billion Swiss francs, compared to 33.4 billion Swiss francs in the same period last year. Diagnostic business sales reached 10.7 billion Swiss francs (approximately 12.1 billion US dollars), remaining flat compared to the same period last year.

Boston ScientificAnnouncement of Q3 2024 Financial Results. Net sales for the quarter were $4.209 billion, compared to $3.527 billion in the same period last year. Net profit attributable to the company's ordinary shareholders for the quarter was $469 million, compared to $505 million in the same period last year.

Henry ScheinAnnouncement of Q3 2024 Financial Results: Net sales for the quarter were $3.174 billion, compared to $3.162 billion in the same period last year. Net profit attributable to the company for the quarter was $99 million, compared to $137 million in the same period last year.

Cardinal HealthAnnounced Financial Results for the First Fiscal Quarter Ended September 30, 2024. Quarterly revenue was $52.3 billion, compared to $54.7 billion in the same period last year. Net profit attributable to the company for the quarter was $416 million, compared to a net loss of $12 million in the same period last year. Revenue from the medical products and distribution business was $3.1 billion, compared to $3 billion in the same period last year; quarterly profit was $8 million, compared to $12 million in the same period last year.

Owens & MinorAnnouncement of Q3 2024 Results: Quarterly revenue was $2.721 billion, compared to $2.592 billion in the same period last year. Quarterly operating profit was $24.2 million, compared to $23.8 million in the same period last year. Quarterly net loss was $12.8 million, compared to a net loss of $6.4 million in the same period last year.

Baxter International Inc.Announcement of Q3 2024 Financial Results: Net sales for the quarter were $2.699 billion, compared to $2.599 billion in the same period last year. Operating profit for the quarter was $155 million, compared to $179 million in the same period last year. Net profit attributable to shareholders for the quarter was $140 million, compared to $2.508 billion in the same period last year.

Solventum (formerly 3M Health Care Business)Announcement of Q3 2024 Financial Results: Total net sales for the quarter were $2.082 billion, compared to $2.074 billion in the same period last year. Quarterly net profit was $122 million, compared to $460 million in the same period last year.

Intuitive SurgicalAnnouncement of Q3 2024 Financial Results. Total revenue for the quarter was $2.038 billion, compared to $1.744 billion in the same period last year. Net profit attributable to the company for the quarter was $565 million, compared to $416 million in the same period last year. Revenue from instruments and accessories during the period was $1.264 billion, compared to $1.071 billion in the same period last year. The total number of da Vinci Surgical Systems installed reached 9,539, representing a 15% year-over-year increase.

Zimmer Biomet Holdings IncAnnouncement of Q3 2024 Results: Quarterly Net Sales of $1.824 Billion, Compared to $754 Million in the Same Period Last Year. Quarterly Operating Profit of $280 Million, Compared to $267 Million in the Same Period Last Year. Quarterly Net Profit Attributable to the Company of $249 Million, Compared to $163 Million in the Same Period Last Year.

TerumoAnnouncement of Financial Results for the First Half of the Fiscal Year Ending September 30, 2024 (April-September). Revenue for the period was 508.685 billion yen (approximately 3.28 billion USD), compared to 443.874 billion yen for the same period last year, representing a year-on-year increase of 14.6%. Operating profit for the period was 87.716 billion yen, compared to 66.492 billion yen for the same period last year, representing a year-on-year increase of 31.9%. Net profit attributable to owners of the parent company for the period was 63.204 billion yen, compared to 50.092 billion yen for the same period last year, representing a year-on-year increase of 26.2%.

Olympus (OLYMPUS)Announcement of Financial Results for the First Half of the Fiscal Year Ending September 30, 2024 (April-September). Revenue for the period was 474.029 billion yen (approximately 3.059 billion USD), compared to 431.593 billion yen for the same period last year, representing a year-on-year increase of 9.8%. Operating profit for the period was 70.53 billion yen, compared to 3.767 billion yen for the same period last year. Net profit attributable to owners of the parent company for the period was 48.978 billion yen, compared to 216.296 billion yen for the same period last year.

Fujifilm HoldingsFinancial Results for the First Half of the Fiscal Year Ending September 30, 2024 (April-September) Released. During this period, the group's sales revenue increased by 9.1% year-on-year, reaching 1,514.7 billion yen. Operating profit reached 135.6 billion yen, an increase of 8% year-on-year, while net profit attributable to the group decreased by 2.9% year-on-year, reaching 110.3 billion yen. Across all business areas, medical health business revenue increased by 5.3% year-on-year, reaching 472 billion yen (approximately 3.046 billion US dollars). Electronic materials business revenue increased by 34.6% year-on-year, reaching 217.8 billion yen. Imaging business revenue increased by 17.4% year-on-year, reaching 257.2 billion yen. Business innovation revenue increased by 1.5% year-on-year, reaching 567.7 billion yen.

Mindray MedicalRelease of the Third Quarter Report for 2024. In the first three quarters, the company achieved operating revenue of 29.485 billion yuan (approximately 4.073 billion US dollars), an increase of 7.99% year-on-year; net profit attributable to shareholders was 10.637 billion yuan, up 8.16% year-on-year. In the third quarter, operating revenue reached 8.954 billion yuan (approximately 1.237 billion US dollars), an increase of 1.43% year-on-year; net profit attributable to shareholders was 3.076 billion yuan, a decrease of 9.31% year-on-year.

Canon Group (Canon)Release of Q3 2024 Financial Report. Group turnover for the quarter increased by 5.3% year-on-year to 1,079.806 billion yen. Operating profit increased by 18.8% year-on-year to 98.164 billion yen. Net profit attributable to the company increased by 10.7% year-on-year to 68.763 billion yen. Among them, the turnover in the printing business sector increased by 7.1% compared with the same period last year, reaching 610.9 billion yen. The turnover in the medical business sector remained basically the same as last year, at 132.3 billion yen (approximately 8.54 billion US dollars). The turnover in the imaging business sector increased by 8.6% year-on-year to 229.6 billion yen. The turnover in the industrial business sector increased by 9.6% year-on-year to 71.272 billion yen.

Ophthalmology

EssilorLuxotticaAnnouncement of Q3 2024 Financial Results: Total quarterly revenue reached €6.437 billion, compared to €6.294 billion in the same period last year. Revenue from Professional Solutions amounted to €3.017 billion (approximately $3.198 billion), up from €2.978 billion in the previous year. Consumer business revenue was €3.42 billion, compared to €3.316 billion in the same period last year.

AlconAnnouncement of Q3 2024 Financial Results. Net sales and other revenue for the quarter were $2.454 billion, compared to $2.329 billion in the same period last year. Operating profit for the quarter was $332 million, compared to $293 million in the same period last year. Net profit for the quarter was $263 million, compared to $204 million in the same period last year.

Bausch+LombAnnouncement of Q3 2024 Financial Results: Quarterly revenue was $1.196 billion, compared to $1.007 billion in the same period last year. Quarterly operating profit was $43 million, compared to $40 million in the same period last year. Quarterly net profit attributable to the company was $4 million, compared to a net loss of $84 million in the same period last year.

In 2024, despite challenges such as global economic fluctuations and supply chain issues, the healthcare sector achieved steady growth through continuous R&D investment, market strategy adjustments, and the exploration of emerging markets. Whether industry giants like Medtronic and Johnson & Johnson, or specialized companies such as Intuitive Surgical and Alcon, all demonstrated remarkable adaptability and innovation capabilities. Looking ahead, the industry is expected to deliver more innovative outcomes that enhance the quality of human life.